GILEAD SCIENCES, INC. for GILEAD SCIENCES INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
Taxation/Internal Revenue Code TAX
Implementation of the Tax Cuts and Jobs Act of 2017 (P.L. 115-97)
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
Health Issues HCR
Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| CHARLES M. CLAPTON | — |
| COOKAB HASHEMI | — |
| DAVID PULLIAM | — |
Medicare/Medicaid MMM
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act H.R.3 - The Lower Drug Costs Now Act H.R.259 - Medicaid Extenders Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| CHARLES M. CLAPTON | — |
| COOKAB HASHEMI | — |
| DAVID PULLIAM | — |
Budget/Appropriations BUD
Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R.2740 - HHS Appropriations, 2020 H.R.3164 - FDA Appropriations, 2020 H.R.2839 - Department of State, Foreign Operations, and Related Programs Appropriations Act, 2020 H.R.4378 - Continuing Appropriations Act and Health Extenders Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON | — |
| COOKAB HASHEMI | — |
| DAVID PULLIAM | — |
Trade (domestic/foreign) TRD
International trade and protection of intellectual property; compulsory licensing and other IP issues in multiple countries.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
Veterans VET
Education related to hepatitis C and HIV.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON | — |
| COOKAB HASHEMI | — |
| DAVID PULLIAM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.